The Anderson Analysis

YYZLabs Capital is launching from Singapore with a bold 'two-way' investment model. Can this new boutique firm deliver or will its lack of a track record prove a fatal flaw?

Thai researchers are turning fat into insulin-producing cells to cure pet diabetes. But can this breakthrough navigate the path from lab to leash?

NAMA is seeking experts for its 2027 show, setting the stage for innovation in AI, micro markets, and unattended retail. Here's what it means.

Former Uber exec David Reich launches Fambot to automate family logistics. Can AI truly lighten the mental load that plagues millions of modern parents?

Beyond the hype of new storefronts, High Tide's latest expansion reveals a disciplined, data-driven strategy that is reshaping Canada's cannabis market.

The wan AIChef ultra promises to autonomously 'see, think, and cook.' But does this $4,000 AI robot truly solve the dinner dilemma or just serve up hype?

As the MICHELIN Guide returns to Las Vegas, Guy Savoy's star isn't just a win; it's a masterclass in the enduring business model of unwavering excellence.

Halcones Precious Metals pays for another delay at its Polaris project, battles for land access in a Chilean court, and abruptly replaces its CEO.

With its 52nd straight dividend hike, UBSI signals stability. But a new 5% stock buyback hints at a bolder strategy for acquisitions in a consolidating market.

Golden State Dermatology's acquisition of a Colorado Springs practice signals a larger trend. Can physician-led networks scale without losing the patient-first ethos?

A small dealership acquisition in Lakeland reveals a national strategy. Spark Dealer Group is rolling up local OPE businesses, but can it scale without losing its soul?

Flexpoint's rapid scaling and sale of ArtesRx to Linden reveals a high-stakes model for specialized care. But can profit motives and patient needs coexist?

John Stamos will receive the Bob Saget Legacy Award, but the real story is the SRF's brilliant model: turning comedy and connection into millions for science.

With an $800M credit line, Ensign is poised for aggressive growth. This move signals deep lender confidence and a strategy to dominate the post-acute care market.

T. Rowe Price's acquisition of ETF pioneer F/m Investments is more than a deal; it's a bet on the future. Can a legacy firm buy its way out of outflows?

A new fintech partnership promises to inject instant liquidity into the volatile produce market. But can technology truly solve the deep-rooted issues of waste and risk?

Hollister's motorcycle rally deployed AI gun detection and mobile surveillance. We analyze if this tech is a scalable blueprint for safety or a risky trade-off.

With M&A failures tied to leadership, a new service digs beyond reference checks for deep, behavioral intelligence. Is this the end of costly 'post-close surprises'?

A new trial for refractory melanoma relies on a breakthrough manufacturing platform from NTx Bio. This is how automation is making personalized vaccines a reality.

The launch of Ice Spice's "In Ha Mood" is more than a fragrance. It's a calculated blueprint for brand revival in the age of social commerce.